Eli Lilly stock slipped on Thursday after the drugmaker significantly slashed its full-year earnings guidance on the back of a deal spree.
What disappointed was the outlook. Lilly slashed its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90. “Lilly had another strong quarter in Q3 as Mounjaro and Verzenio continued to gain momentum,” David A. Ricks, the group’s chairman and CEO, said in a statement. “Lilly executed on business development priorities in the third quarter including multiple acquisitions that expand our already robust pipeline.”
Nigeria Nigeria Latest News, Nigeria Nigeria Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly Stock Slumps as Earnings Guidance Slashed DramaticallyLilly slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90.
Read more »